Options traders are leaning bearish on IQV ahead of Q2 results due July 28. The put-call ratio sits at 1.16 — nearly two standard deviations above its 20-day mean of 0.92. That's the clearest signal in the current data.
The stock gained 4.4% on July 23 and is up 23.5% over the past month. Yet the options market is hedging hard rather than chasing the move.
The PCR of 1.16 compares to a 20-day mean of 0.92 and a standard deviation of 0.125. The z-score of 1.97 puts current put positioning near the top of the recent range. The 52-week PCR high is 2.65, so there is room for further skew — but the direction is clear. Traders are buying protection.
The previous earnings print supports some caution. Q1 results on May 5 moved the stock 9.6% in a single day. The July 22 result produced a 2.8% move. History shows this name can gap meaningfully, in either direction.
Short interest tells a different story. SI has fallen 14% over the past month to 2.66% of free float — a multi-month low. That is a low absolute level and not the primary driver here. What is notable is the divergence: short sellers are covering, but options traders are buying puts. Those are not the same actors making the same bet.
The cost to borrow rose 56% week-on-week to 0.70%. That sounds sharp, but availability remains exceptionally loose at 4,908% — more than 123 million shares available to borrow against current short positions. The CTB move reflects a small change in a very uncrowded borrow market. It is not a squeeze signal.
The analyst setup was covered in depth in ORTEX's July 19 earnings preview. In brief: Mizuho raised its target to $230 and Baird to $249, both maintaining Outperform. Morgan Stanley downgraded to Equal-Weight in mid-June with a $200 target. The consensus mean sits at $232 — roughly 12% above current levels. The Street is split, which is consistent with the options market hedging rather than positioning directionally.
The ORTEX short score has drifted lower, from 35.7 on July 9 to 34.1 on July 22. The score has been declining steadily. That reflects the unwinding of short positions rather than any new bullish signal.
What to watch: Whether the PCR holds elevated or normalises into the July 28 print — and whether the Q2 result resolves the growth deceleration debate that has divided the Street since Morgan Stanley's June downgrade.
See the live data behind this article on ORTEX.
Open IQV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
